Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Read more about Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE.
Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise? Read more about Cyclooxygenase-2 inhibitors and other NSAIDs in urology: current peril or future promise?
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Read more about Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Read more about Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE.
Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Read more about Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance.
Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Read more about Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer.
Who is the average patient presenting with prostate cancer? Read more about Who is the average patient presenting with prostate cancer?
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Read more about Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Spontaneous jejunal intussusception after open radical nephrectomy. Read more about Spontaneous jejunal intussusception after open radical nephrectomy.
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Read more about Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
